contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


tomas-blomquist-appointed-new-ceo-of-c-rad

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

C-Rad

Tomas Blomquist is a highly experienced international leader with over 30 years in the industry, including two decades in global commercial roles and five years as CEO of Biotage AB (publ). ...

<div class="mfn-preamble"><p><strong>Tomas Blomquist is a highly experienced international leader with over 30 years in the industry, including two decades in global commercial roles and five years as CEO of Biotage AB (publ). The board believes that Tomas is an excellent candidate to implement C-RAD's strategy, to achieve the company's full potential and thereby create increased share value. Tomas will take office on February 2, 2026.</strong></p></div><div class="mfn-body"><p>Tomas Blomquist has extensive experience in international leadership positions within Life Science and Medtech and most recently came from the role as CEO of Biotage 2019–2024. He has extensive experience in building profitable growth companies, driving transformation and creating structure, speed and focus in complex environments. He has previously held leading commercial positions at Abbott, Alere, Analyticon Biotechnologies and Johnson &amp; Johnson, among others. Tomas Blomquist will start his employment on February 2, 2026.</p><p>This means that the company's acting CEO and CFO Linda Frölén will return to her role as CFO and that board member Peter Simonsbacka will end his consulting assignment.</p><p>Kristina Willgård, Chairwoman of the Board, says: “I am very pleased that we have been able to attract Tomas Blomquist to take over as CEO of C-RAD. He has solid expertise and extensive experience from international markets and from creating shareholder value in listed companies.”</p><p>Tomas Blomquist comments on the appointment: “I am very honored to be appointed as the new CEO of C-RAD. The company has a very exciting future with significant growth potential and is positioned in important areas of cancer care. I look forward to working with the organization to further develop the company's operations.”</p><p><strong>For further information, please contact:</strong><br>Kristina Willgård, Chairwoman mobile +46 (0) 70 510 1223<br>Tomas Blomquist, appointed CEO mobile +46 (0) 70 523 0163</p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-26 14:25 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-image"><p><strong class="mfn-heading-1">Image Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/a3664da4-1793-4658-b336-8e2def3437c8/tomas-blomquist.jpeg">Tomas Blomquist</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/27f04c26-6b10-4f49-8034-5a91048865a6/tomas-blomquist-appointed-new-ceo-of-c-rad.pdf" class="mfn-generated mfn-primary">Tomas Blomquist appointed new CEO of C-RAD</a></p></div>